Search Result

Results for "

CKDs

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) AMPK (1) Anaplastic lymphoma kinase (ALK) (1) Antibiotic (1) Apoptosis (7) Bacterial (1) Bcl-2 Family (2) Biochemical Assay Reagents (3) Cannabinoid Receptor (2) CaSR (3) CDK (3) CETP (1) CMV (2) Cyclin G-associated Kinase (GAK) (1) Cytochrome P450 (1) DNA/RNA Synthesis (2) Drug Derivative (2) Drug Isomer (1) Drug Metabolite (1) Dynamin (1) E1/E2/E3 Enzyme (2) Endogenous Metabolite (5) Environmental Pollutants (1) Ferroportin (1) GABA Receptor (1) Glutaminase (1) Glycosidase (1) Guanylate Cyclase (2) HDAC (1) Hepcidin (1) HIV Integrase (1) HSV (2) iGluR (1) Interleukin Related (2) JNK (1) Keap1-Nrf2 (3) MetAP (3) Microtubule/Tubulin (3) MMP (1) NF-κB (6) NO Synthase (2) p38 MAPK (1) PI3K (1) Procollagen C Proteinase (1) Prostaglandin Receptor (2) Reactive Oxygen Species (ROS) (5) Reference Standards (2) SARS-CoV (2) Sodium Phosphate Cotransporter (1) SphK (2) TGF-beta/Smad (2) TGF-β Receptor (2) Thrombin (1) TNF Receptor (1) Topoisomerase (4) TRP Channel (3) VD/VDR (1) Virus Protease (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (15) Cardiovascular Disease (11) Endocrinology (7) Infection (8) Inflammation/Immunology (21) Metabolic Disease (19) Neurological Disease (3)

By Targets:

Akt (1)

AMPK (1)

Anaplastic lymphoma kinase (ALK) (1)

Antibiotic (1)

Apoptosis (7)

Bacterial (1)

Bcl-2 Family (2)

Biochemical Assay Reagents (3)

Cannabinoid Receptor (2)

CaSR (3)

CDK (3)

CETP (1)

CMV (2)

Cyclin G-associated Kinase (GAK) (1)

Cytochrome P450 (1)

DNA/RNA Synthesis (2)

Drug Derivative (2)

Drug Isomer (1)

Drug Metabolite (1)

Dynamin (1)

E1/E2/E3 Enzyme (2)

Endogenous Metabolite (5)

Environmental Pollutants (1)

Ferroportin (1)

GABA Receptor (1)

Glutaminase (1)

Glycosidase (1)

Guanylate Cyclase (2)

HDAC (1)

Hepcidin (1)

HIV Integrase (1)

HSV (2)

iGluR (1)

Interleukin Related (2)

JNK (1)

Keap1-Nrf2 (3)

MetAP (3)

Microtubule/Tubulin (3)

MMP (1)

NF-κB (6)

NO Synthase (2)

p38 MAPK (1)

PI3K (1)

Procollagen C Proteinase (1)

Prostaglandin Receptor (2)

Reactive Oxygen Species (ROS) (5)

Reference Standards (2)

SARS-CoV (2)

Sodium Phosphate Cotransporter (1)

SphK (2)

TGF-beta/Smad (2)

TGF-β Receptor (2)

Thrombin (1)

TNF Receptor (1)

Topoisomerase (4)

TRP Channel (3)

VD/VDR (1)

Virus Protease (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (15)

Cardiovascular Disease (11)

Endocrinology (7)

Infection (8)

Inflammation/Immunology (21)

Metabolic Disease (19)

Neurological Disease (3)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13324

Bardoxolone methyl Maximum Cited Publications 41 Publications Verification RTA 402; NSC 713200; CDDO Methyl ester	Keap1-Nrf2 SARS-CoV Virus Protease	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Bardoxolone (CDDO; RTA 401) methyl is an orally active and blood-brain-barrier-penetrant activator of Nrf2 and an inhibitor of SARS-CoV-2 3CL protease. Bardoxolone methyl inhibits SARS-CoV-2 replication in Vero cells with an EC₅₀ value of 0.29 μM. Bardoxolone methyl increases levels of pNrf2 and HO-1, inhibits inflammatory mediators like pNFκB and MCP-1. Bardoxolone methyl activates the Nrf2 pathway to enhance antioxidant and anti-inflammatory responses, inhibits viral replication, and improves mitochondrial function. Bardoxolone methyl can be used in research on chemotherapy-induced neuropathic pain (CINP), COVID-19, and chronic kidney disease (CKD) .

HY-N1428C

Ferric citrate 5 Publications Verification Iron(III) citrate; Zerenex	Reactive Oxygen Species (ROS) Antibiotic	Metabolic Disease
Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-111431A

p-Cresyl sulfate potassium Maximum Cited Publications 6 Publications Verification p-Tolyl sulfate potassium	Endogenous Metabolite JNK p38 MAPK	Metabolic Disease Inflammation/Immunology
p-Cresyl sulfate potassium is a uremic toxin that binds to a prototype protein. p-Cresyl sulfate potassium activates the JNK and p38 MAPK signaling pathways. p-Cresyl sulfate potassium has pro-inflammatory activity .

HY-13566A

Belotecan hydrochloride 2 Publications Verification CKD-602	Topoisomerase	Cancer
Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative.

HY-13566

Belotecan 2 Publications Verification CKD-602 free base	Topoisomerase Apoptosis	Cancer
Belotecan (CKD-602 free base) is a DNA topoisomerase I inhibitor. Belotecan induces cell apoptosis and cell-cycle arrest. Belotecan is a camptothecin analogue with anti-tumor effects, it can be used for the research of cancer .

HY-B0504

Creatinine Maximum Cited Publications 6 Publications Verification NSC13123	Endogenous Metabolite GABA Receptor iGluR	Infection Neurological Disease Metabolic Disease Cancer
Creatinine (NSC13123) is an orally active, blood-brain barrier-permeable modulator of GABAA and NMDA receptors, with activities of antioxidation and metabolic regulation. Creatinine is generated via non-enzymatic conversion of creatine and phosphocreatine in muscle. Creatinine serum levels correlate with muscle mass, glomerular filtration rate, and extrarenal clearance, serving as an evaluation biomarker for renal function, muscle mass, and clinical outcomes, and used for perioperative renal risk assessment. In addition, Creatinine can induce specific Cryptococcus species to produce creatinine deiminase and act as their nitrogen source, while it can be secreted via renal tubules. Creatinine is widely used in research related to various diseases such as neurodegenerative diseases, psychiatric disorders, acute kidney injury, chronic kidney disease, and renal failure .

HY-126397

MnTBAP chloride 5+ Cited Publications	NF-κB	Inflammation/Immunology
MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research .

HY-N2995

Poricoic acid A 1 Publications Verification Poricoic acid A(F)	NF-κB Keap1-Nrf2 AMPK TGF-beta/Smad Reactive Oxygen Species (ROS)	Inflammation/Immunology Cancer
Poricoic acid A can be isolated from Poria cocos. Poricoic acid A is an orally active anti-tumor agent. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFκB/Nrf2 axis. Poricoic acid A also attenuatea fibroblast activation and abnormal extracellular matrix remodeling in renal fibrosis by activating AMPK and inhibiting Smad3. Poricoic acid A significantly reduces the magnitude of rise in serum creatinine and urea levels in rat model when combined with Melatonin. Poricoic acid A ameliorates renal fibrosis and podocyte injury by attenuating oxidative stress and inflammation through regulating NF-κB and Nrf2 in IRI rodent model in combination with Melatonin .

HY-13102

UK-383367	Procollagen C Proteinase	Others
UK-383367 is an orally available pro-collagen C-protease inhibitor (BMP-1) with an IC₅₀ value of 44 nM. UK-383367 can reduce renal fibrosis and inflammation in chronic kidney disease (CKD) and may be used to study postoperative skin scarring .

HY-112671

CDDO-dhTFEA RTA dh404	Keap1-Nrf2 NF-κB Apoptosis	Cardiovascular Disease Inflammation/Immunology
CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB . CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats .

HY-12953

R-268712	TGF-β Receptor TGF-beta/Smad Anaplastic lymphoma kinase (ALK)	Cardiovascular Disease Inflammation/Immunology Cancer
R-268712 is an orally active and selective ALK-5 inhibitor, with an IC₅₀ of 2.5 nM. R-268712 inhibits the phosphorylation of Smad3 in a dose-dependent manner with an IC₅₀ of 10.4 nM. R-268712 suppresses glomerulonephritis as well as glomerulosclerosis by inhibiting TGF-β signaling, which can be used in studies of renal fibrosis and cancer .

HY-13569A

Beraprost sodium TRK-100; ML 1129 sodium	Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost sodium (TRK-100), a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium (TRK-100) is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost sodium (TRK-100) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13995B

Sevelamer carbonate 1 Publications Verification	Drug Derivative	Metabolic Disease
Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995) .

HY-113493

4-Pyridoxic acid	Endogenous Metabolite	Metabolic Disease
4-Pyridoxic acid is an endogenous substrate of renal organic anion transporters (OAT1/3) and a catabolite of vitamin B6. 4-Pyridoxic acid is excreted through OAT1/3-mediated tubular active secretion, which can reflect OAT1/3 activity. Elevated plasma concentrations of 4-Pyridoxic acid are associated with decreased OAT1/3 activity in chronic kidney disease (CKD) and can be used as a biomarker to reflect the severity of knee osteoarthritis (KOA) and lumbar spondylosis (LS) .

HY-P11178

Corisin	Apoptosis SARS-CoV	Infection Metabolic Disease Inflammation/Immunology
Corisin is a pro-apoptotic small peptide produced by Staphylococcus species. Corisin binds to serum albumin to target organs such as the lungs and kidneys, induces cellular senescence, apoptosis and epithelial-mesenchymal transition, and accelerates the progression of organ fibrosis including pulmonary fibrosis and diabetic renal fibrosis. Corisin levels are closely associated with coronavirus disease 2019 (COVID-19), diabetic chronic kidney disease (CKD), non-diabetic CKD, and idiopathic pulmonary fibrosis (IPF) .

HY-P99512

Zampilimab UCB-7858	Glutaminase	Endocrinology
Zampilimab (UCB-7858) is a monoclonal antibody against transglutaminase 2 (TG2). Zampilimab inhibits TG2 crosslinking transamidation activity with an IC₅₀ of 0.25 nM and a K_d of <50 pM. Zampilimab improves renal fibrosis .

HY-119572

Sodium zirconium cyclosilicate	Biochemical Assay Reagents	Inflammation/Immunology
Sodium zirconium cyclosilicate is an orally administered, non-absorbed, novel, inorganic microporous zirconium silicate compound, is a highly selective cation exchanger that selectively removes excess K ⁺ in vivo. Sodium zirconium cyclosilicate can be used in research of chronic kidney disease (CKD) .

HY-120897

NS-3-008 hydrochloride	Bcl-2 Family Apoptosis	Inflammation/Immunology
NS-3-008 hydrochloride is an orally active transcriptional inhibitor of G0/G1 switch 2 (G0s2) with an IC₅₀ of 2.25 μM. NS-3-008 hydrochloride can be used for chronic kidney disease .

HY-109136

Runcaciguat 1 Publications Verification BAY 1101042	Guanylate Cyclase	Cardiovascular Disease Metabolic Disease
Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic kidney disease (CKD) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF) .

HY-109106A

Upacicalcet sodium SK-1403; AJT240; PLS240	CaSR	Endocrinology
Upacicalcet sodium is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet sodium reduces serum intact parathyroid hormone (iPTH) and serum Ca ²⁺ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet sodium sodium improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet sodium sodium inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet sodium is useful for studying SHPT .

HY-18944

FIT-039	CDK HSV CMV DNA/RNA Synthesis	Infection
FIT-039 is a selective, ATP-competitive and orally active CDK9 inhibitor with an IC₅₀ of 5.8 μM for CKD9/cyclin T1. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits replication of HSV-1 (IC₅₀ of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses.

HY-123572

Bis-T-23 AG1717	Dynamin HIV Integrase	Infection Metabolic Disease Inflammation/Immunology
Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .

HY-13566AS

Belotecan-d7 hydrochloride	Topoisomerase	Cancer
Belotecan-d₇ (hydrochloride) is the deuterium labeled Belotecan hydrochloride. Belotecan hydrochloride (CKD-602 hydrochloride), a Topoisomerase I inhibitor, is a synthetic camptothecin derivative .

HY-109109

Alteminostat CKD-581	HDAC Apoptosis	Cancer
Alteminostat (CKD-581) is a potent HDAC inhibitor. Alteminostat inhibits the class I-II HDAC family via histone H3 and tubulin acetylation. Alteminostat can be used for lymphoma and multiple myeloma research .

HY-14811

Beloranib ZGN-440; CKD-732 free base	MetAP NF-κB	Metabolic Disease
Beloranib (ZGN-440; CKD-732 free base) is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib can be used in research on obesity and hypothalamic obesity .

HY-W416250

p-Cresol glucuronide	Drug Metabolite	Cardiovascular Disease
p-Cresol glucuronide, a metabolite of p-cresol, is a prototype protein-bound uremic toxin. p-Cresol glucuronide is associated with chronic kidney disease (CKD) .

HY-141411A

Zevaquenabant (S)-MRI-1867	Cannabinoid Receptor NO Synthase	Metabolic Disease
Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD) .

HY-145150

TRPC5-IN-1 1 Publications Verification	TRP Channel	Metabolic Disease
TRPC5-IN-1 (Compound 6j) is a selective TRPC5 inhibitor with 50.5 % Inhibition for TRPC5 at 3 μM. TRPC5-IN-1 can be used for the research of chronic kidney disease (CKD) .

HY-116078

CKD-519	CETP	Cardiovascular Disease
CKD-519 is a selective and potent cholesteryl ester transfer protein (CETP) inhibitor, which inhibits CETP-mediated transfer of cholesteryl ester in human serum with an IC₅₀ of 2.3 nM .

HY-47030

Ferric citrate hydrate	Environmental Pollutants Biochemical Assay Reagents	Metabolic Disease
Ferric citrate hydrate, an orally active iron supplement, is an efficacious phosphate binder. Ferric citrate hydrate can be used for iron deficiency anemia and chronic kidney disease (CKD) research .

HY-P99198

Fletikumab NNC 0109-0012	Interleukin Related	Inflammation/Immunology
Fletikumab (NNC0109-0012) is a monoclonal antibody targeting to IL-20. Fletikumab can be used for inflammation research, such as rheumatoid arthritis .

HY-W674241A

4-Ethylphenyl sulfate sodium	Endogenous Metabolite Apoptosis Bcl-2 Family Reactive Oxygen Species (ROS)	Neurological Disease Cancer
4-Ethylphenyl sulfate sodium is an orally active and brain-penetrant gut microbial metabolite. 4-Ethylphenyl sulfate sodium downregulates Bcl2 expression, upregulates Bax expression, and induces cancer cell apoptosis via the endogenous apoptotic pathway. 4-Ethylphenyl sulfate sodium induces G2/M cell cycle arrest and reactive oxygen species (ROS) production. 4-Ethylphenyl sulfate sodium impairs oligodendrocyte maturation, reduces oligodendrocyte-neuron interactions, decreases axonal myelination levels, and shifts the oligodendrocyte population toward immature precursor cells. 4-Ethylphenyl sulfate sodium alters brain region-specific neural activity and functional connectivity in mice, and correlates with anxiety-like behaviors in mice .

HY-120268A

SLM6031434 hydrochloride	SphK	Inflammation/Immunology
SLM6031434 hydrochloride is the hydrochloride salt form of SLM6031434 (HY-120268). SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC₅₀ value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .

HY-103653

CKD-731	MetAP	Cardiovascular Disease Cancer
CKD-731 is a Fumagillin (HY-B0751) analogue. CKD-731 inhibits the proliferation of calf pulmonary artery endothelial cells (CPAE), lymphoma EL-4 cells and murine leukemia P388D1 cells. CKD-731 exerts the effect of inhibiting MetAP-2 activity and blocking angiogenesis. CKD-731 can be used for the research of anti-angiogenesis-related cancer .

HY-13598A

Valecobulin hydrochloride CKD-516 hydrochloride	Microtubule/Tubulin	Cancer
Valecobulin hydrochloride (CKD-516 hydrochloride) is a valine proagent of S516 (HY-130233) and a vascular disrupting agent (VDA). Valecobulin hydrochloride is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors .

HY-13598

Valecobulin CKD-516	Microtubule/Tubulin	Cancer
Valecobulin (CKD516) is a valine proagent of (S516) and a vascular disrupting agent (VDA). Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors .

HY-122052

UK‑396082	Thrombin	Metabolic Disease
UK‑396082 is a potent thrombin activated fibrinolytic inhibitor (TAFI) inhibitor. UK‑396082 increases plasmin activity and induces a parallel decrease in ECM levels. UK‑396082 can be used in research of chronic kidney disease (CKD) .

HY-153092

Avenciguat BI-685509	Guanylate Cyclase	Cardiovascular Disease Metabolic Disease
Avenciguat (BI-685509) is a potent and orally active sGC activator. Avenciguat restores cyclic guanosine monophosphate (cGMP) and improves functionality of nitric oxide (NO) pathways. Avenciguat can be used in research of chronic kidney disease (CKD) and diabetic kidney disease (DKD) .

HY-14811A

Beloranib hemioxalate ZGN-440 hemioxalate; ZGN-433 hemioxalate; CDK732 hemioxalate	NF-κB MetAP	Metabolic Disease
Beloranib (ZGN-440; CKD-732 free base) hemioxalate is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib hemioxalate blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib hemioxalate significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib hemioxalate also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib hemioxalate can be used in research on obesity and hypothalamic obesity .

HY-105291

CKD-711	Glycosidase Bacterial	Infection Metabolic Disease
CKD-711 is an orally active aminooligosaccharide α-glucosidase inhibitor with an IC₅₀ of 78 μg/mL. CKD-711 also inhibits porcine intestinal maltase and sucrose with IC₅₀ values of 2.5 and 0.5 μg/mL. CKD-711 shows selective antibacterial activity against Comamonas terrigena. CKD-711 can be used for the researches of infection and metabolic disease, such as diabetes .

HY-109106

Upacicalcet SK-1403 free acid; AJT240 free acid; PLS240 free acid	CaSR	Endocrinology
Upacicalcet is a non-peptide calcimimetic that acts as a CaSR agonist (EC₅₀ = 10.8 nM). Upacicalcet reduces serum intact parathyroid hormone (iPTH) and serum Ca2+ levels, reducing hypocalcemia and gastrointestinal complications. Upacicalcet improves vascular calcification and bone disorders in the Adenine (HY-B0152)-induced secondary hyperparathyroidism (SHPT) rat model. Upacicalcet inhibits cortical pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD). Upacicalcet is useful for studying SHPT .

HY-13566R

Belotecan (Standard) CKD-602 free base (Standard)	Topoisomerase Apoptosis Reference Standards	Cancer
Belotecan (Standard) is the analytical standard of Belotecan. This product is intended for research and analytical applications. Belotecan (CKD-602 free base) is a DNA topoisomerase I inhibitor. Belotecan induces cell apoptosis and cell-cycle arrest. Belotecan is a camptothecin analogue with anti-tumor effects, it can be used for the research of cancer .

HY-18944R

FIT-039 (Standard)	CDK HSV CMV DNA/RNA Synthesis	Infection
FIT-039 (Standard) is the analytical standard of FIT-039. This product is intended for research and analytical applications. FIT-039 is a selective, ATP-competitive and orally active CDK9 inhibitor with an IC50 of 5.8 μM for CKD9/cyclin T1. FIT-039 does not inhibit other CDKs and other kinases. FIT-039 inhibits replication of HSV-1 (IC50 of 0.69 μM), HSV-2, human adenovirus, and human CMV. FIT-039 is a promising antiviral agent for inhibiting drug-resistant HSVs and other DNA viruses.

HY-111314

NZ 419 5-Hydroxy-1-methylhydantoin	Reactive Oxygen Species (ROS)	Inflammation/Immunology
NZ 419 (5-Hydroxy-1-methylhydantoin) is a metabolite of creatinine and an antioxidant with oral activity, which has the ability to scavenge hydroxyl radicals (•OH). NZ 419 can inhibit the progression of chronic kidney disease (CKD) in rats .

HY-13569AR

Beraprost sodium (Standard) TRK-100 (Standard); ML 1129 sodium (Standard)	Reference Standards Prostaglandin Receptor	Cardiovascular Disease Inflammation/Immunology
Beraprost (sodium) (Standard) is the analytical standard of Beraprost (sodium). This product is intended for research and analytical applications. Beraprost sodium, a prostacyclin analog, is a stable and orally active proagent of PGI2. Beraprost sodium is a potent vasodilator, has the potential for pulmonary arterial hypertension treatment through expanding renal vessels, improving microcirculation . Beraprost (sodium) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-P6441

KP-6	β-catenin Wnt	Inflammation/Immunology
KP-6, a polypeptide, is a Wnt/β-catenin signal inhibitor. KP-6 inhibits TGF-β and blocks rush fibrosis signal path crucial in vivo. KP-6 suppresses Renal tissues damage and renal fibrosis, and reverse the course of disease of chronic kidney disease (CKD) .

HY-175985

MPO-IN-9	Reactive Oxygen Species (ROS)	Inflammation/Immunology
MPO-IN-9 is a selective inhibitor of myeloperoxidase (MPO), with an IC₅₀ value of 3.9 nM. MPO-IN-9 inhibits MPO-mediated ROS production and protects NO-dependent vascular function by blocking MPO's chlorination and peroxidation cycles. MPO-IN-9 can be used for the study of diseases such as chronic kidney disease (CKD), non-alcoholic steatohepatitis (NASH) .

HY-120268

SLM6031434	SphK	Inflammation/Immunology
SLM6031434 is a highly selective sphingosine kinase 2 (SphK2) inhibitor with an IC₅₀ value of 0.4 μM for SphK2. SLM6031434 exerts anti-fibrotic effects by increasing sphingosine accumulation and Smad7 expression. SLM6031434 demonstrates effective anti-fibrotic efficacy in a unilateral ureteral obstruction (UUO)-induced tubulointerstitial fibrosis mouse model. SLM6031434 can be used for the study of proteinuric kidney diseases or chronic kidney disease (CKD) .

HY-130233

S516	Microtubule/Tubulin	Cancer
S516 (Compound 22) is an active metabolite of CKD-516 and a potent tubulin polymerization inhibitor with an IC₅₀ of 4.29 μM. S516 has marked antitumor activity .

HY-14863

Lunacalcipol CTA-018	VD/VDR Cytochrome P450	Others Endocrinology
Lunacalcipol (CTA-018), as a vitamin D analogue, has a dual role in the pathogenesis of Chronic Kidney Disease (CKD), as an agonist of vitamin D receptor and an antagonist of cytochrome P450 enzyme 24-hydroxylase. Lunacalcipol binds to VDR and regulates transcriptional activity of VDR by influencing ligand binding affinity, ligand-dependent coactivator recruitment or inhibitory factor dissociation, efficiency of ligand entry into target cells, tissue specificity and different metabolism of ligand. Lunacalcipol can be used in the study of CKD, especially Secondary Hyperparathyroidism (sHPT) .

Cat. No.	Product Name

HY-L229

Nephrotoxicity Compound Library

158 compounds

Kidneys are one of the vital organs in the human body. Due to their exposure to higher concentrations of circulating drugs or metabolites, they are highly susceptible to drug-induced renal injury (DIRI). According to statistics, drug-induced kidney injury accounts for approximately 20% of nephrotoxicity reports and can lead to acute kidney injury (AKI), chronic kidney disease (CKD), or even end-stage renal disease (ESRD). Early detection of drug nephrotoxicity is crucial for preventing irreversible kidney damage. Research into its mechanisms can help optimize clinical medication by adjusting dosages or avoiding combinations of nephrotoxic drugs. Additionally, predicting drug-induced nephrotoxicity in early drug development can reduce the risk of late-stage R&D failure.

MCE offers 158 nephrotoxicity compounds that have been clearly reported by the FDA to be associated with kidney injury. This library can be used for studying molecular mechanisms of nephrotoxicity or developing novel biomarkers.

Cat. No.	Product Name	Target	Research Area